SAJA Pharmaceuticals

sajaonline.net

SAJA is a joint venture between the premier Saudi healthcare company, Tamer, the Saudi partner, the (SA) in SAJA and two of the leading Japanese pharmaceutical companies, Daiichi Sankyo Co., Ltd. and Astellas Pharma Inc., the Japanese partners, the (JA) in SAJA. Both companies are major players in the Japanese healthcare sector, each with an impressive portfolio of ethical medicines.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

ON DEMAND PHARMACEUTICALS ANNOUNCES PREFERRED SUPPLIER RELATIONSHIP WITH AZZUR GROUP

On Demand Pharmaceuticals, Azzur Group | June 02, 2022

news image

On Demand Pharmaceuticals, Inc. an innovative technology company transforming the way medicines are made, announced that it has signed a Preferred Supplier agreement with Azzur Group through 2024. The transformation of ODP's Rockville Headquarters into a State-of-the-Art cGMP Medicine Manufacturing facility began with Azzur in the fall of 2020. Azzur collaborated in designing ODP's GMP Roadmap and helped develop the strategy and execution plan for ushering in this latest a...

Read More

PHARMA SEES MORE POST-M&A REBRANDS THAN OTHER INDUSTRIES—AND IT DOES THEM BETTER, TOO

Fiercepharma | June 03, 2020

news image

To rebrand or not? It’s a big question for pharma companies before and after acquisitions—and one answered with "yes" more often than in other industries. Pharma, in fact, was the most prolific rebrander in Brand Finance’s recent research assessing the value of rebrands across 25 industries. It's also one of the most successful, with rebrands in pharma generating average returns of 13.8%, according to Brand Finance calculations. The main reason? Most acquired phar...

Read More

Business Insights

ASYMCHEM AND LANOVA MEDICINES ENTER INTO PARTNERSHIP AGREEMENT, EXPANDING BIOLOGICAL CAPABILITIES

Asymchem | September 17, 2021

news image

Asymchem today announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration. The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem's recently co...

Read More

Pharmacy Market

WALGREENS BOOTS ALLIANCE COMPLETES MAJORITY SHARE ACQUISITION OF CARECENTRIX

Walgreens Boots Alliance and CareCentrix | September 01, 2022

news image

Walgreens Boots Alliance, Inc. announced it has completed its previously announced majority share acquisition of CareCentrix, Inc.—the leading independent home-centered platform that coordinates care to the home for health plans, patients and providers. The majority investment in CareCentrix accelerates Walgreens Health’s capabilities in delivering quality healthcare across a spectrum of settings including primary care, specialty pharmacy care, post-acute care and home care. <...

Read More
news image

Business Insights

ON DEMAND PHARMACEUTICALS ANNOUNCES PREFERRED SUPPLIER RELATIONSHIP WITH AZZUR GROUP

On Demand Pharmaceuticals, Azzur Group | June 02, 2022

On Demand Pharmaceuticals, Inc. an innovative technology company transforming the way medicines are made, announced that it has signed a Preferred Supplier agreement with Azzur Group through 2024. The transformation of ODP's Rockville Headquarters into a State-of-the-Art cGMP Medicine Manufacturing facility began with Azzur in the fall of 2020. Azzur collaborated in designing ODP's GMP Roadmap and helped develop the strategy and execution plan for ushering in this latest a...

Read More
news image

PHARMA SEES MORE POST-M&A REBRANDS THAN OTHER INDUSTRIES—AND IT DOES THEM BETTER, TOO

Fiercepharma | June 03, 2020

To rebrand or not? It’s a big question for pharma companies before and after acquisitions—and one answered with "yes" more often than in other industries. Pharma, in fact, was the most prolific rebrander in Brand Finance’s recent research assessing the value of rebrands across 25 industries. It's also one of the most successful, with rebrands in pharma generating average returns of 13.8%, according to Brand Finance calculations. The main reason? Most acquired phar...

Read More
news image

Business Insights

ASYMCHEM AND LANOVA MEDICINES ENTER INTO PARTNERSHIP AGREEMENT, EXPANDING BIOLOGICAL CAPABILITIES

Asymchem | September 17, 2021

Asymchem today announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration. The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem's recently co...

Read More
news image

Pharmacy Market

WALGREENS BOOTS ALLIANCE COMPLETES MAJORITY SHARE ACQUISITION OF CARECENTRIX

Walgreens Boots Alliance and CareCentrix | September 01, 2022

Walgreens Boots Alliance, Inc. announced it has completed its previously announced majority share acquisition of CareCentrix, Inc.—the leading independent home-centered platform that coordinates care to the home for health plans, patients and providers. The majority investment in CareCentrix accelerates Walgreens Health’s capabilities in delivering quality healthcare across a spectrum of settings including primary care, specialty pharmacy care, post-acute care and home care. <...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us